Fragment-Based Drug Discovery Market is estimated to be worth around USD 1.6 billion by 2030
Roots Analysis is pleased to announce the publication of its recent study, titled, “Fragment-based Drug Discovery Market: Library and Service Providers, 2020-2030.”
Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of this approach over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
- A detailed review of the overall landscape of fragment-based drug discovery library and service providers.
- Elaborate profiles of the companies providing libraries and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered).
- An analysis of the partnerships that have been established in the recent past.
- A detailed analysis on acquisition targets.
- An insightful competitiveness analysis of fragment-based drug discovery library and service providers.
- An analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.
Get Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/fragment-based-drug-discovery/309.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Technique
- X-ray Crystallography
- Nuclear Magnetic Resonance
- Surface Plasmon Resonance
- Other Screening Techniques
Type of Service
- Library Screening
- Fragment Screening
- Fragment Optimization
End User
- Industry Players
- Non-Industry Players
Key Geographical Region
- North America (US and Canada)
- Europe (UK, France, Germany, Spain, Italy, and rest of Europe)
- Asia-Pacific (China, Japan, India, and rest of Asia-Pacific / rest of the world)
Key companies covered in the report
- 2bind
- Charles River Laboratories
- ChemAxon
- ComInnex
- Creative Biolabs
- Creative Biostructure
- CRELUX
- Domainex
- Evotec
- Red Glead Discovery
- SARomics Biostructures
- Shanghai ChemPartner
- Sygnature Discovery
- Vernalis Research
Request for Customization:
https://www.rootsanalysis.com/reports/309/request-customization.html
Chapter Outlines
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for fragment-based drug discovery and its likely evolution in the short-mid-term and long term.
Chapter 3 provides an introduction to the process of drug discovery and development. In addition, the chapter focuses on the concept of fragment-based drug discovery, highlighting its key advantages and drawbacks. It also features a brief discussion on the opportunities and the likely future trends in this field.
Chapter 4 provides a detailed overview of the current market landscape of fragment-based drug discovery, including information on library and service providers, type of product (library and technology), type of service offered (fragment screening and fragment optimization), type of technique used (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance, and other screening techniques), other services offered (target identification / validation, hit identification, hit-to-lead / lead generation and lead optimization) and end user (industry players and non-industry players).
Chapter 5 includes detailed profiles of the companies providing library and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered). Each profile features a brief overview of the company, its financial information (if available), fragment-based library and service portfolio, information on other drug discovery services, recent developments and an informed future outlook.
Chapter 6 features an elaborate analysis of the partnerships that have been inked among various stakeholders in this domain, during 2015-2020. It includes a brief description of partnership models (such as research and development agreements, mergers and acquisitions, product development and commercialization agreements, distribution and supply agreements, service alliances, and commercialization agreements) adopted by the stakeholders.
Chapter 7 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
Chapter 8 provides an insightful competitiveness analysis of fragment-based drug discovery library and service providers, featuring a two-dimensional scatter plot representation. It highlights the key players in this domain, taking into consideration the supplier power (based on the year of establishment of service provider) and key specifications, such as number of fragment libraries and number of screening techniques.
Chapter 9 provides an analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
Also have a Look on Our Upcoming Research Reports
Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
Spinal Muscular Atrophy Market, 2021-2031